Scarica l'app Stockscreener
9.02
3.84%
-0.36
Dopo l'orario di chiusura:
9.05
0.03
+0.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCRX Giù?
Forum
Previsione
Precedente Chiudi:
$9.38
Aprire:
$9.31
Volume 24 ore:
7.82M
Relative Volume:
1.47
Capitalizzazione di mercato:
$2.26B
Reddito:
$874.84M
Utile/perdita netta:
$263.86M
Rapporto P/E:
7.4973
EPS:
1.2031
Flusso di cassa netto:
$327.41M
1 W Prestazione:
-5.65%
1M Prestazione:
+4.52%
6M Prestazione:
+23.06%
1 anno Prestazione:
+21.40%
Intervallo 1D:
$8.92
$9.35
Intervallo di 1 settimana:
$8.92
$9.73
Portata 52W:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Nome
Biocryst Pharmaceuticals Inc
Settore
Telefono
919-859-1302
Indirizzo
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.02 | 2.26B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
18.74 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.94 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.93 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.08 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
564.81 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-18 | Ripresa | Evercore ISI | Outperform |
| 2025-10-15 | Ripresa | TD Cowen | Buy |
| 2025-10-01 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Iniziato | Wedbush | Outperform |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-09-18 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-13 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-02-22 | Aggiornamento | Needham | Hold → Buy |
| 2022-11-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-10 | Iniziato | Oppenheimer | Outperform |
| 2021-08-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-08-03 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Iniziato | Cowen | Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Overweight |
| 2020-06-17 | Iniziato | BTIG Research | Neutral |
| 2020-05-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Ripresa | Piper Jaffray | Overweight |
| 2018-08-08 | Ripresa | JP Morgan | Overweight |
| 2018-07-17 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Iniziato | Seaport Global Securities | Neutral |
| 2018-01-02 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Iniziato | Barclays | Equal Weight |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2017-02-16 | Iniziato | Ladenburg Thalmann | Buy |
| 2016-08-12 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Reiterato | FBR Capital | Outperform |
| 2016-02-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Downgrade | Needham | Buy → Hold |
Mostra tutto
Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets - finance.yahoo.com
BioCryst Pharmaceuticals, Inc. (BCRX) stock price, news, quote and history - Yahoo Finance Singapore
BCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioCryst (BCRX) soars 13% on acquisition buzz - MSN
BioCryst Pharmaceuticals Inc (BO1.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
BioCryst (BCRX) rallies 7.10% on acquisition buzz - MSN
Technical Reactions to BCRX Trends in Macro Strategies - Stock Traders Daily
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
12 new BioCryst hires receive stock awards tied to 157,300 shares - Stock Titan
Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
BCRX Forecast, Price Target & Analyst Ratings | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst Pharmaceuticals Stock: Navigating Biotech Innovation and Investor Opportunities in Rare Dis - AD HOC NEWS
BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak - MSN
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - marketbeat.com
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co. - MarketBeat
Rate Cut: Is BioCryst Pharmaceuticals Inc subject to activist investor interest2026 Momentum & Reliable Breakout Stock Forecasts - baoquankhu1.vn
BioCryst 2025 slides: path to $1B revenue, Navenibart expands portfolio - Investing.com Canada
Earnings call transcript: BioCryst Q4 2025 shows strong growth, stock dips - Investing.com Australia
Earnings call transcript: BioCryst Q4 2025 shows strong growth, stock dips By Investing.com - Investing.com South Africa
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
Vanguard amends Schedule 13G — BioCryst (BCRX) ownership shown as 0 - Stock Titan
Does BioCryst Pharmaceuticals (BCRX) Still Offer Value After Recent Share Price Strength? - Sahm
BioCryst Shares Remain Undervalued, RBC Says - marketscreener.com
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $13 - Moomoo
RBC Capital reiterates BioCryst stock rating on takeout potential - Investing.com
RBC Capital reiterates BioCryst stock rating on takeout potential By Investing.com - Investing.com Canada
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN
Insider Sell: Theresa Heggie Sells 49,933 Shares of BioCryst Pha - GuruFocus
Major Insider Move at BioCryst Shakes Up Investor Buzz - TipRanks
Buybacks Report: Is BioCryst Pharmaceuticals Inc benefiting from interest rate changes2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Hereditary Angioedema Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Biocryst Pharmaceuticals Insider Sold Shares Worth $504,823, According to a Recent SEC Filing - MarketScreener
Option exercise and sale by BioCryst (BCRX) director Theresa Heggie - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap UpWhat's Next? - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Trading the Move, Not the Narrative: (BCRX) Edition - Stock Traders Daily
Aug Sectors: Is BioCryst Pharmaceuticals Inc benefiting from interest rate changes2026 Spike Watch & Fast Gain Swing Trade Alerts - baoquankhu1.vn
BioCryst (BCRX) soars 10.8% on swing to profits - MSN
Form 144 BIOCRYST PHARMACEUTICALS INC For: 20 March - Investing.com
[144] BIOCRYST PHARMACEUTICALS INC SEC Filing - stocktitan.net
Biocryst Pharmaceuticals Inc Azioni (BCRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):